REYON Pharmaceutical Co., Ltd.

KSE 102460.KS

REYON Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2023: USD 190.94 M

REYON Pharmaceutical Co., Ltd. Shareholders' Equity is USD 190.94 M for the year ending December 31, 2023, a -2.45% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

REYON Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2022 was USD 195.73 M, a -4.64% change year over year.
REYON Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2021 was USD 205.26 M, a -2.82% change year over year.
REYON Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2020 was USD 211.22 M, a 11.28% change year over year.
REYON Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2019 was USD 189.81 M, a -5.01% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

KSE: 102460.KS

REYON Pharmaceutical Co., Ltd.

CEO	Ms. Soon-Ock Jung
IPO Date	June 10, 2010
Location	South Korea
Headquarters	416 Yeongdong-daero
Employees	466
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Non-Alcoholic Beverages Personal Care Pet Food Soft Drinks & Sodas

Description

REYON Pharmaceutical Co., Ltd. manufactures and sells finished medicines and APIs in South Korea and internationally. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; migraine drugs; miscellaneous cardiovascular system drugs; neuromuscular disorder related drugs; nootropics and neurotonics; NSAIDs; respiratory stimulants; skeletal muscle relaxants; and vasodilators. REYON Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years